Published in Angiology on January 01, 1982
Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet (1994) 6.89
Antithrombotic treatment and atrial fibrillation. BMJ (1992) 5.33
Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med (2001) 4.39
Monitoring adverse reactions to new drugs: "restricted release" or "monitored release"? Br Med J (1977) 4.20
Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med (2000) 3.90
Phenol injection of the sympathetic chain. Br J Surg (1970) 3.73
Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer (2003) 3.44
Intra-arterial temazepam. BMJ (1992) 3.40
Poisoning by bites of the saw-scaled or carpet viper (Echis carinatus) in Nigeria. Q J Med (1977) 3.27
Postmarketing surveillance of the safety of cimetidine: 12 month mortality report. Br Med J (Clin Res Ed) (1983) 2.90
Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women: the British Regional Heart Study. Stroke (1999) 2.89
Analgesic nephropathy: clinical syndrome and prognosis. Br Med J (1971) 2.77
Post marketing surveillance of captopril (for hypertension): a preliminary report. Br J Clin Pharmacol (1987) 2.56
Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation (2001) 2.43
Plasma fibrinogen and coronary risk factors: the Scottish Heart Health Study. J Clin Epidemiol (1990) 2.43
Cimetidine and gastric cancer: preliminary report from post-marketing surveillance study. Br Med J (Clin Res Ed) (1982) 2.40
Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer (2004) 2.39
Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation (1996) 2.32
Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur Heart J (2000) 2.30
Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified serum C1 inactivator. J Lab Clin Med (1970) 2.17
Studies on a complex mechanism for the activation of plasminogen by kaolin and by chloroform: the participation of Hageman factor and additional cofactors. J Clin Invest (1969) 2.14
Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J (1999) 2.08
Tissue plasminogen activator and leucocyte elastase as predictors of cardiovascular events in subjects with angina pectoris: Edinburgh Artery Study. Eur Heart J (2000) 2.08
Post-marketing surveillance of the safety of cimetidine: twelve-month morbidity report. Q J Med (1985) 2.07
Acute exercise and markers of endothelial injury in peripheral arterial disease. Eur J Vasc Endovasc Surg (1997) 2.07
Do women exhibit greater differences in established and novel risk factors between diabetes and non-diabetes than men? The British Regional Heart Study and British Women's Heart Health Study. Diabetologia (2011) 2.06
Infarcts after surgery. BMJ (1995) 2.04
The yellow card: mark II. BMJ (1990) 2.00
Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol (2001) 1.96
Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial. Lancet (1983) 1.94
Death from thyrotoxicosis. Lancet (1973) 1.93
ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation. BMJ (1996) 1.85
Idiopathic gangrene in African children. Br Med J (1967) 1.85
Postmarketing surveillance of the safety of cimetidine: mortality during second, third, and fourth years of follow up. Br Med J (Clin Res Ed) (1985) 1.78
Benzodiazepine drugs in general medical patients. Br Med J (1976) 1.74
An evaluation of the impact of a multidisciplinary team, in a single centre, on treatment and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer (2005) 1.71
Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut (2000) 1.69
Renin and acute renal failure: studies in man. Br Med J (1970) 1.66
Effects of physiological concentrations of vasopressin on haemostatic function in man. Clin Sci (Lond) (1985) 1.64
Impaired cell mediated immunity in haemophilia in the absence of infection with human immunodeficiency virus. Br Med J (Clin Res Ed) (1986) 1.64
Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) (2001) 1.63
Vascular damage and factor-VIII-related antigen in the rheumatic diseases. Rheumatol Int (1987) 1.62
Adverse reactions to potassium chloride. Q J Med (1974) 1.60
Helicobacter pylori infection and coronary heart disease in the North Glasgow MONICA population. Eur Heart J (1997) 1.60
The relationship between blood viscosity and blood pressure in a random sample of the population aged 55 to 74 years. Eur Heart J (1993) 1.60
Cystic adventitial disease of the popliteal artery. Br Med J (1967) 1.59
Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis. Am Heart J (1996) 1.59
Detection of drug-induced disease. Br J Clin Pharmacol (1979) 1.56
Calculation of predictive odds for possible carriers of heamophilia. Thromb Diath Haemorrh (1975) 1.51
Blood loss in the Kolff twin-coil artificial kidney. Nephron (1970) 1.50
Is aspirin safe for patients with heart failure? Br Heart J (1995) 1.49
Thromboprophylaxis--which treatment for which patient? J Bone Joint Surg Br (2000) 1.47
Effect of furosemide on antibiotic-induced renal damage in rats. J Infect Dis (1972) 1.46
Tissue plasminogen activator inhibition in diabetes mellitus. Diabetes Care (1989) 1.45
Association of fibrinolytic tests with outcome of acute upper-gastrointestinal-tract bleeding. Lancet (1993) 1.45
Fibrinogen genotype and risk of peripheral atherosclerosis. Lancet (1992) 1.44
Saddle embolus as first presentation of left atrial myxoma in a 14-year-old girl. Scott Med J (1988) 1.44
A European view on the North American fifth consensus on antithrombotic therapy. Chest (2000) 1.43
Improving prospects for employment of the haemophiliac. Br Med J (1980) 1.43
Perioperative myocardial infarction in peripheral vascular surgery. BMJ (1996) 1.43
Fetal corticotrophin-releasing hormone mRNA, but not phosphatidylserine-exposing microparticles, in maternal plasma are associated with factor VII activity in pre-eclampsia. J Thromb Haemost (2007) 1.43
Relation between extent of coronary artery disease and blood viscosity. Br Med J (1980) 1.42
Effect of combined oestrogen-progestogen oral contraceptives, oestrogen, and progestogen on antiplasmin and antithrombin activity. Lancet (1970) 1.42
The potentiation of platelet aggregation and adhesion by heparin in vitro and in vivo. Clin Sci Mol Med (1973) 1.42
Abdominal aortic aneurysm: a preventable cause of death? J R Coll Surg Edinb (1990) 1.40
Management of urgent intact abdominal aortic aneurysms. J R Coll Surg Edinb (1990) 1.40
Venous and arterial thrombosis in airline passengers. J R Soc Med (1998) 1.40
In vivo measurements of fibrin formation and fibrinolysis in operable breast cancer. Thromb Haemost (1989) 1.39
Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J (1995) 1.38
The value of ultrasonography in the diagnosis of abdominal aortic aneurysm. Scott Med J (1975) 1.38
Intensive hospital monitoring study of intravenous cimetidine. Arch Intern Med (1986) 1.38
Blood rheology in vitro and in vivo. Baillieres Clin Haematol (1987) 1.36
Dental disease, fibrinogen and white cell count; links with myocardial infarction? Scott Med J (1993) 1.36
Abnormal blood viscosity and haemostasis in long-standing retinal vein occlusion. Br J Ophthalmol (1983) 1.34
Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin Chem (2000) 1.34
Relation of atrial fibrillation and high haematocrit to mortality in acute stroke. Lancet (1983) 1.34
Retinopathy associated with high-dose interferon alfa-2b therapy. Am J Ophthalmol (2001) 1.33
Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis (1981) 1.33
Potassium supplements in patients receiving long-term diuretics for oedema. Q J Med (1976) 1.31
Microangiopathic haemolytic anaemia and the pathogenesis of malignant hypertension. Lancet (1969) 1.31
Coagulation, fibrinolysis and platelet function in pre-eclampsia, essential hypertension and placental insufficiency. J Obstet Gynaecol Br Commonw (1971) 1.29
Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study. Br J Ophthalmol (1996) 1.29
The effects of age and cigarette-smoking on blood and plasma viscosity in men. Scott Med J (1980) 1.28
Necrosis, haemorrhage and complement depletion following bites by the spitting cobra (Naja nigricollis). Q J Med (1976) 1.27
How periodontal disease may contribute to cardiovascular disease. Periodontol 2000 (2000) 1.26
Record linkage study of hypokalaemia in hospitalized patients. Postgrad Med J (1986) 1.25
Hyponatraemia during carbamazepine treatment. Br Med J (1977) 1.25
Haemostatic changes during dialysis associated with thrombus formation on dialysis membranes. Br Med J (1972) 1.24
Severe hypokalemia in hospitalized patients. Arch Intern Med (1979) 1.24